VYGR

Voyager Therapeutics Inc. (VYGR) is a cutting-edge clinical-stage gene therapy company based in Cambridge, Massachusetts, specializing in the innovative treatment of severe neurological disorders. Leveraging its proprietary adeno-associated virus (AAV) platform, Voyager is committed to developing targeted gene therapies that offer potentially transformative solutions for patients suffering from chronic neurological conditions. The company boasts a robust pipeline of investigational therapies and strategic partnerships that enhance its position as a leader in addressing significant unmet medical needs in the central nervous system. With its focus on advancing breakthrough treatment options, Voyager Therapeutics is well-positioned to drive impactful changes in the field of neurology and improve patient outcomes.